L1: Entry 2 of 4 File: PGPB Jun 13, 2002

PGPUB-DOCUMENT-NUMBER: 20020072082
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020072082 A1

TITLE: Ion-exchange resin / enzyme activity assay

PUBLICATION-DATE: June 13, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Karsten, Thomas P.	O'Fallon	IL	US	
Currie, Mark G.	Marlborough	MA	US	
Moore, William M.	St. Charles	MO	US	

US-CL-CURRENT: 435/18; 435/7.9

CLAIMS:

We claim:

1. A method of determining enzyme activity comprising: contacting a compound selected from the group consisting of enzymes, enzyme fragments and abzymes with a labeled substrate to form a differentially-charged product; selectively coupling either the substrate or the differentially-charged product to an ion-exchange resin thereby substantially separating the substrate from the differentially-charged product; and determining the amount of substrate remaining or differentially-charged product formed using a measuring means.

2. A method of determining enzyme activity comprising: contacting a compound selected from the group consisting of enzymes, enzyme fragments and abzymes with a labeled substrate thereby effecting the conversion of the substrate to a differentially-charged product; stopping the conversion before all of the substrate present has been converted to the differentially-charged product; selectively coupling either the substrate or the differentially-charged product to an ion-exchange resin thereby substantially separating the substrate from the differentially-charged product in a single step; and determining the amount of substrate remaining or differentially-charged product formed using a measuring means; wherein the stopping step and coupling step are carried out concurrently or sequentially.

3. The method of claim 1 or 2 wherein the product is bound to the resin.

4. The method of claim 1 or 2 wherein the substrate is bound to the resin.

5. The method of claim 1 or 2 wherein the product or substrate measured is coupled to the resin

6. The method of claim 1 or 2 wherein the product or substrate measured is in solution

7. The method of claim 1 or 2 wherein said enzyme is a kinase.

8. The method of claim 1 or 2 wherein said method is conducted in a multiple-well format.

9. The method of claim 8 wherein the format comprises at least about 96 wells.

10. The method of claim 8 wherein said format is automated.

11. The method of claim 1 or 2 wherein said high-throughput format is conducted on a microchip.

12. The method of claim 1 or 2 wherein said enzyme is selected from the group consisting of GFAT, Nitric Oxide Synthase, Methionine Aminopeptidase, Asn Syn, PFK, p38, I-kappa kinase 1, I-kappa kinase 2, TBK1, MAPKAP 2, GTase, , OGTase, and Cyclooxygenase.

13. A method for identifying a molecule, compound, or composition that affects the activity of an enzyme, comprising: contacting the enzyme with a test sample comprising a molecule, compound, or composition; contacting the enzyme with a labeled substrate to form a differentially-charged product; selectively coupling either the substrate or the differentially-charged product to an ion-exchange resin thereby substantially separating the substrate from the differentially-charged product; determining the amount of substrate remaining or differentially-charged product formed using a measuring means; and comparing the amount of substrate remaining or differentially-charged product formed with a control.

14. The method of claim 13 wherein said enzyme is selected from the group consisting of GFAT, Nitric Oxide Synthase, Methionine Aminopeptidase, Asn Syn, PFK, p38, I-kappa kinase 1, I-kappa kinase 2, TBK1, MAPKAP 2, GTase, , OGTase, and Cyclooxygenase.

15. The method of claim 13 wherein the control is an izozyme and the method is used to identifying a compound or composition that preferentially or specifically effects an enzyme over its isozyme.

16. A method of determining bi-functional enzyme activity comprising: contacting an enzyme with a first labeled substrate to form a first differentially-charged product; contacting the enzyme with a second labeled substrate to form a second differentially-charged product; selectively coupling to an ion-exchange resin a member selected from the group consisting of the first substrate, the second substrate, the first product, and the second product, thereby substantially separating said member from the remaining members of the group; and determining the amount of said member using a measuring means.

17. A method of determining bi-functional enzyme activity comprising: contacting an enzyme with a first labeled substrate to form a first differentially-charged product; contacting the enzyme with a second labeled substrate to form a second differentially-charged product; selectively coupling to an ion-exchange resin two members selected from the group consisting of the first substrate, the second substrate, the first product, and the second product, thereby substantially separating said members from the remaining members; and determining the amount of said members using a measuring means.

18. The method of claim 17 wherein said determination of bi-functional enzyme activity is conducted separately.

19. A method of determining the kinetics of an enzyme reaction, comprising: contacting a compound selected from the group consisting of enzymes, enzyme fragments and abzymes with a labeled substrate to form a differentially-charged product; stopping the reaction at various timepoints; selectively coupling either the substrate or the differentially-charged product to an ion-exchange resin thereby substantially separating the substrate from the differentially-charged product; determining the amount of substrate remaining or differentially-charged product formed using a measuring means; and comparing the amount of substrate remaining or product formed at the timepoints.

20. A method of determining the functional sites on an enzyme comprising: contacting a compound with a plurality of point-mutated enzymes with a labeled substrate to form a differentially-charged product; selectively coupling either the substrate or the differentially-charged product to an ion-exchange resin thereby substantially separating the substrate from the differentially-charged product; determining the amount of substrate remaining or differentially-charged product formed using a measuring means; and comparing the amount of substrate remaining or differentially-charged product formed from the plurality of enzymes.

21. A method of evaluating the selective coupling of an enzyme and a reactant comprising contacting a compound with an enzyme with a plurality of labeled substrates to form differentially-charged products; selectively coupling either the substrates or the differentially-charged products to an ion-exchange resin thereby substantially separating the substrates from the differentially-charged products; determining the amount of substrate remaining or differentially-charged products formed using a measuring means; and comparing the amount of substrate remaining or differentially-charged products formed from the plurality of substrates.

22. A kit for determining enzyme activity wherein said kit comprises at least three members of the group consisting of: An enzyme, a labeled ligand, a buffer solution, an ion-exchange resin, and a stop-buffer solution

23. A kit of claim 22 for determining enzyme activity wherein said kit comprises at least three members of the group consisting of: An enzyme, a labeled ligand, a buffer solution, an ion-exchange resin, and a stop-buffer solution

24. A kit of claim 23 for determining enzyme activity wherein said kit comprises at least three members of the group consisting of: An enzyme, a labeled ligand, a buffer solution, an ion-exchange resin, and a stop-buffer solution

25. A kit for determining enzyme activity comprising an enzyme, a labeled ligand, a buffer solution, an ion-exchange resin, and a stop-buffer solution

26. A compound discovered using the method of claims 1 or 2.

Previous Doc Next Doc Go to Doc#

Hit List

Clear | Generate Collection | Print | Fwd Refs | Bkwd Refs | Generate OACS

Search Results - Record(s) 1 through 4 of 4 returned.

☐ 1. Document ID: US 20040058875 A1

Using default format because multiple data bases are involved.

L1: Entry 1 of 4 File: PGPB Mar 25, 2004

PGPUB-DOCUMENT-NUMBER: 20040058875
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040058875 A1

TITLE: Methods of treating dry eye disorders

PUBLICATION-DATE: March 25, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Gamache, Daniel A.	Arlington	TX	US	

US-CL-CURRENT: 514/15; 514/256, 514/405

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw. De

☐ 2. Document ID: US 20020072082 A1

L1: Entry 2 of 4 File: PGPB Jun 13, 2002

PGPUB-DOCUMENT-NUMBER: 20020072082
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020072082 A1

TITLE: Ion-exchange resin / enzyme activity assay

PUBLICATION-DATE: June 13, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Karsten, Thomas P.	O'Fallon	IL	US	
Currie, Mark G.	Marlborough	MA	US	
Moore, William M.	St. Charles	MO	US	

US-CL-CURRENT: 435/18; 435/7.9

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw. De

☐ 3. Document ID: WO 2004026406 A1, US 20040058875 A1

L1: Entry 3 of 4 File: DWPI Apr 1, 2004

DERWENT-ACC-NO: 2004-294257
DERWENT-WEEK: 200431
COPYRIGHT 2004 DERWENT INFORMATION LTD
TITLE: Treatment of dry eye and other disorders requiring wetting of eye, comprising administering cytokine synthesis inhibitor to mammal

INVENTOR: GAMACHE, D A

PRIORITY-DATA: 2002US-412463P (September 20, 2002), 2003US-0650006 (August 26, 2003)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
WO 2004026406 A1	April 1, 2004	E	000	A61P027/02
US 20040058875 A1	March 25, 2004		006	A61K038/08

INT-CL (IPC): A61 K 31/192; A61 K 31/416; A61 K 31/505; A61 K 31/506; A61 K 31/551; A61 K 31/616; A61 K 38/08; A61 P 27/02

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw De

☐ 4. Document ID: US 20020072082 A1

L1: Entry 4 of 4 File: DWPI Jun 13, 2002

DERWENT-ACC-NO: 2002-589473
DERWENT-WEEK: 200263
COPYRIGHT 2004 DERWENT INFORMATION LTD
TITLE: Rapid high-throughput ion exchange resin assay for determining enzyme activity, comprises contacting enzymes with labeled substrate and coupling substrate or charged product to ion-exchange resin to separate substrate from charged product

INVENTOR: CURRIE, M G; KARSTEN, T P ; MOORE, W M

PRIORITY-DATA: 2000US-213354P (June 22, 2000), 2001US-0888008 (June 22, 2001)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
US 20020072082 A1	June 13, 2002		007	C12Q001/34

INT-CL (IPC): C12 Q 1/34; G01 N 33/53; G01 N 33/542

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw De

Clear | Generate Collection | Print | Fwd Refs | Bkwd Refs | Generate OACS

Terms	Documents
I-kappa kinase	4

Display Format: - Change Format

Previous Page Next Page Go to Doc#

L4: Entry 38 of 51 File: USPT Jul 22, 2003

US-PAT-NO: 6596485
DOCUMENT-IDENTIFIER: US 6596485 B2

TITLE: Green fluorescent protein fusions with random peptides

DATE-ISSUED: July 22, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Anderson; David	San Bruno	CA		
Bogenberger; Jakob Maria	Menlo Park	CA		

US-CL-CURRENT: 435/6; 424/278.1, 435/69.1, 536/23.4

CLAIMS:

We claim:

1. A method of screening for bioactive peptides conferring a particular phenotype comprising: a) providing cells containing a fusion nucleic acid comprising i) a first nucleic acid encoding a GFP scaffold protein; ii) a second nucleic acid encoding a polyglycine linker fused to the C-terminus of said scaffold protein and iii) a third nucleic acid encoding a random peptide fused to the C-terminus of said linker; under conditions wherein said fusion protein is expressed; and b) assaying said cells for said phenotype,

wherein said phenotype is modulation of an immune response.

2. The method according to claim 1 wherein said cells comprise T-cells and said phenotype is a T-cell response.

3. The method of claim 2, wherein said T-cell response is proliferation in response to antigen presentation.

4. The method according to claim 1 wherein said cells comprise B cells and said phenotype is a interaction with a specific immunoglobulin.

5. The method according to claim 1 wherein said phenotype is cytokine production.

6. The method according to claim 5, wherein said cells are macrophages.

7. The method according to claim 5, wherein said cells are monocytes.

8. The method according to claim 1 wherein said cells are mononuclear leukocytes and said phenotype is antigen processing.

9. The method according to claim 1 wherein said phenotype is release of inflammatory mediators.

10. The method of claim 9 wherein said cells comprise mononuclear leukocytes.

11. The method of claim 9 wherein said cells comprise mast cells.

12. The method of claim 9 wherein said cells comprise eosinophils.

13. The method of claim 1 wherein said fusion nucleic acid further comprises a fusion partner.

14. The method of claim 13 wherein said fusion partner comprises a presentation structure.

15. The method of claim 13, wherein said fusion partner comprises a targeting sequence.

16. The method of claim 13 wherein said fusion partner comprises a rescue sequence.

17. The method of claim 13 wherein said fusion partner comprises a stability sequence.

18. The method of claim 1 wherein said random peptide is a biased random peptide.

19. The method of claim 1 wherein said method comprises providing a cellular library comprising a library of fusion nucleic acids, each fusion nucleic acid comprising said first, second and third nucleic acids, and wherein a plurality of said third nucleic acids are different.

20. The method of claim 1 wherein said GFP is a wild type GFP.

21. The method of claim 1 wherein said GFP is a variant GFP.

22. The method of claim 1 wherein said providing is by transfection of said cells with a retrovirus comprising said fusion nucleic acid.

Previous Doc Next Doc Go to Doc#

Hit List

Clear | Generate Collection | Print | Fwd Refs | Bkwd Refs | Generate OACS

Search Results - Record(s) 1 through 9 of 9 returned.

☐ 1. Document ID: US 20040161765 A1

Using default format because multiple data bases are involved.

L5: Entry 1 of 9 File: PGPB Aug 19, 2004

PGPUB-DOCUMENT-NUMBER: 20040161765
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040161765 A1

TITLE: Methods and compositions for identifying disease genes using nonsense-mediated decay inhibition

PUBLICATION-DATE: August 19, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Dietz, Harry C.	Towson	MD	US	
Noensie, Eric	New York	NY	US	

US-CL-CURRENT: 435/6

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWMC | Draw De

☐ 2. Document ID: US 20040072214 A1

L5: Entry 2 of 9 File: PGPB Apr 15, 2004

PGPUB-DOCUMENT-NUMBER: 20040072214
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040072214 A1

TITLE: Novel glycoproteins and methods of use thereof

PUBLICATION-DATE: April 15, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Taylor, Nabil El	Milton	MA	US	
Kiernan, Susan	Wrentham	MA	US	
Campbell, Robert K.	Hopkinton	MA	US	
Kelton, Christie A.	Hopkinton	MA	US	
He, Chaomei			US	

US-CL-CURRENT: 435/6; 435/184, 435/320.1, 435/325, 435/69.2, 530/388.26, 536/23.2

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw De

---

☐ 3. Document ID: US 20040005554 A1

L5: Entry 3 of 9 File: PGPB Jan 8, 2004

PGPUB-DOCUMENT-NUMBER: 20040005554
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040005554 A1

TITLE: Novel glycoproteins and methods of use thereof

PUBLICATION-DATE: January 8, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Tayar, Nabil El	Milton	MA	US	
Campbell, Robert K.	Wrentham	MA	US	
Kelton, Chistie A.	Hopkinton	MA	US	
He, Chaomei	Wellesley	MA	US	

US-CL-CURRENT: 435/6; 424/146.1, 424/94.63, 435/226, 435/320.1, 435/325, 435/69.1, 514/44, 530/388.26, 536/23.2

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw De

---

☐ 4. Document ID: US 20030219786 A1

L5: Entry 4 of 9 File: PGPB Nov 27, 2003

PGPUB-DOCUMENT-NUMBER: 20030219786
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030219786 A1

TITLE: Novel glycoproteins and methods of use thereof

PUBLICATION-DATE: November 27, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Tayar, Nabil El	Milton	MA	US	
Kiernan, Susan	Milton	MA	US	
Campbell, Robert K.	Wrentham	MA	US	
Kelton, Christie A.	Hopkinton	MA	US	
He, Chaomei	Wellesley	MA	US	

US-CL-CURRENT: 435/6; 424/143.1, 435/320.1, 435/325, 435/69.1, 435/7.1, 514/12, 514/44, 530/350, 530/388.22, 536/23.5

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw De

☐ 5. Document ID: US 20030045694 A1

L5: Entry 5 of 9 File: PGPB Mar 6, 2003

PGPUB-DOCUMENT-NUMBER: 20030045694
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030045694 A1

TITLE: Ultra-sensitive detection systems

PUBLICATION-DATE: March 6, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Chait, Brian T.	New York	NY	US	
Latimer, Darin R.	East Haven	CT	US	
Lizardi, Paul M.	Wallingford	CT	US	
Kershnar, Eric R.	New Haven	CT	US	
Morrow, Jon S.	Madison	CT	US	
Roth, Matthew E.	Branford	CT	US	
Mattessich, Martin J.	Woodbridge	CT	US	
McConnell, Kevin J.	Branford	CT	US	

US-CL-CURRENT: 536/23.1

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw De

☐ 6. Document ID: US 6790652 B1

L5: Entry 6 of 9 File: USPT Sep 14, 2004

US-PAT-NO: 6790652
DOCUMENT-IDENTIFIER: US 6790652 B1

TITLE: Method and apparatus for high density format screening for bioactive molecules

DATE-ISSUED: September 14, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Terry; Bernard Robert	Frederiksberg C			DK
Scudder; Kurt Marshall	Virum			DK
Arkhammer; Per Olaf Gunnar	Helsingborg			SE
Thastrup; Ole	Bikeroed			DK

US-CL-CURRENT: 435/287.7; 422/101, 422/50, 422/51, 422/52, 422/55, 422/56, 422/58, 422/68.1, 422/69, 422/81, 422/82.05, 422/82.07, 435/177, 435/178, 435/179, 435/180, 435/182, 435/286.1, 435/287.1, 435/395, 435/4, 435/401, 435/7.2, 435/7.92, 436/147, 436/162, 436/164, 436/165, 436/169, 436/172, 436/174, 436/34, 436/501, 436/55 , 436/800, 436/809, 436/815

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWMC | Draw D

☐ 7. Document ID: US 6436654 B1

L5: Entry 7 of 9 File: USPT Aug 20, 2002

US-PAT-NO: 6436654
DOCUMENT-IDENTIFIER: US 6436654 B1

TITLE: Methods for identifying compounds that modulate HIF-1.alpha.

DATE-ISSUED: August 20, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Berkenstam; Anders	Stockholm			SE
Poellinger; Lorenz	Stockholm			SE

US-CL-CURRENT: 435/7.8; 435/7.2, 530/350

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWMC | Draw D

☐ 8. Document ID: US 6388788 B1

L5: Entry 8 of 9 File: USPT May 14, 2002

US-PAT-NO: 6388788
DOCUMENT-IDENTIFIER: US 6388788 B1

TITLE: Method and apparatus for screening chemical compounds

DATE-ISSUED: May 14, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Harris; Timothy D.	Toms River	NJ		
Hansen; Richard L.	Pennington	NJ		
Karsh; William	Plainsboro	NJ		
Nicklaus; Neal A.	East Windsor	NJ		
Trautman; Jay K.	Pennington	NJ		

US-CL-CURRENT: 359/196; 250/234, 359/204, 359/212, 359/215, 359/226, 359/368, 359/391

☐ 9. Document ID: DE 69824763 E, WO 9845704 A2, AU 9868209 A, EP 986753 A2, JP 2001522454 W, EP 986753 B1, EP 1199564 A2, DE 69804446 E, ES 2173573 T3, US 6518021 B1, US 20030082564 A1, ES 2191575 T1, CA 2450698 A1, CA 2286293 C, EP 1199564 B1, EP 1435519 A1

L5: Entry 9 of 9 File: DWPI Jul 29, 2004

DERWENT-ACC-NO: 1998-594491
DERWENT-WEEK: 200452

TITLE: Determining effect on signalling pathways in live cells from redistribution of luminophores - specifically fusions of green fluorescent protein with a signalling component, and new apparatus, particularly for identifying toxins and potential therapeutic agents

INVENTOR: KASPER, A; PETERSEN BJORN, S ; SCUDDER, K ; THASTRUP, O ; TULLIN, S ; ALMHOLT, K ; ARKHAMMER, P O G ; TERRY, B R ; BJOERN, S P ; ARKHAMMAR, P O G ; SCUDDDR, K ; BJORN, S P

PRIORITY-DATA: 1997DK-0000392 (April 7, 1997)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
DE 69824763 E	July 29, 2004		000	G01N033/50
WO 9845704 A2	October 15, 1998	E	326	G01N033/53
AU 9868209 A	October 30, 1998		000	G01N033/53
EP 986753 A2	March 22, 2000	E	000	G01N033/53
JP 2001522454 W	November 13, 2001		336	G01N033/50
EP 986753 B1	March 27, 2002	E	000	G01N033/53
EP 1199564 A2	April 24, 2002	E	000	G01N033/50
DE 69804446 E	May 2, 2002		000	G01N033/53
ES 2173573 T3	October 16, 2002		000	G01N033/53
US 6518021 B1	February 11, 2003		000	C12Q001/68
US 20030082564 A1	May 1, 2003		000	C12Q001/68
ES 2191575 T1	September 16, 2003		000	G01N033/50
CA 2450698 A1	October 15, 1998	E	000	C12Q001/48
CA 2286293 C	April 6, 2004	E	000	G01N033/50
EP 1199564 B1	June 23, 2004	E	000	G01N033/50
EP 1435519 A1	July 7, 2004	E	000	G01N033/50

1435519 A1 INT-CL (IPC): C07 H 21/04; C07 K 14/435; C12 N 5/06; C12 N 9/12; C12 N 15/82; C12 P 21/02; C12 Q 1/02; C12 Q 1/04; C12 Q 1/25; C12 Q 1/48; C12 Q 1/68; G01 N 21/64; G01 N 33/50; G01 N 33/53; G01 N 33/58

Terms	Documents
L3 and kinase and fluorescent probe	9

Display Format: - Change Format

Previous Page Next Page Go to Doc#

WEST Search History

Hide Items | Restore | Clear | Cancel

DATE: Wednesday, September 22, 2004

Hide?	Set Name	Query	Hit Count
	DB=EPAB; PLUR=YES; OP=ADJ		
☐	L6	WO-9845704-A2.did.	1
	DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI; PLUR=YES; OP=ADJ		
☐	L5	L3 and kinase and fluorescent probe	9
☐	L4	L3 and kinase	51
☐	L3	fusion green fluorescent protein	78
☐	L2	L1 and green fluorescent protein	0
☐	L1	I-kappa kinase	4

END OF SEARCH HISTORY

L1: Entry 1 of 11 File: USPT Feb 10, 2004

US-PAT-NO: 6689575
DOCUMENT-IDENTIFIER: US 6689575 B2
**** See image for Certificate of Correction ****

TITLE: I.kappa.B kinase, subunits thereof, and methods of using same

DATE-ISSUED: February 10, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Karin; Michael	San Diego	CA		
DiDonato; Joseph A.	Westlake	OH		
Rothwarf; David M.	La Jolla	CA		
Hayakawa; Makio	Tokyo			JP
Zandi; Ebrahim	Duarte	CA		

US-CL-CURRENT: 435/15; 435/194, 435/252.3, 435/320.1, 435/325, 435/7.1, 530/350

CLAIMS:

We claim:

1. An isolated human I.kappa.B kinase (IKK) subunit, IKK.beta., wherein said IKK.beta. phosphorylates serine-32 and serine-36 of I.kappa.B.alpha. and has an apparent molecular mass of 87 kiloDaltons as determined by SDS-polyacrylamide gel electrophoresis in an 8% gel under reducing conditions.

2. The isolated IKK.beta. of claim 1, comprising an amino acid sequence as shown in SEQ ID NO: 15.

3. The isolated IKK.beta. of claim 1, wherein said isolated IKK.beta. comprises one or more sequences selected from the group consisting of SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, and SEQ ID NO:20.

4. The isolated IKK.beta. of claim 3, wherein said isolated IKK.beta. comprises two or more sequences selected from the group consisting of SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, and SEQ ID NO:20.

5. The isolated IKK.beta. of claim 4, wherein said isolated IKK.beta. comprises three or more sequences selected from the group consisting of SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, and SEQ ID NO:20.

6. The isolated IKK.beta. of claim 5, wherein said isolated IKK.beta. comprises four or more sequences selected from the group consisting of SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, and SEQ ID NO:20.

7. The isolated IKK.beta. of claim 1, wherein said isolated IKK.beta. comprises SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, and SEQ ID NO:20.

8. The isolated IKK.beta. of claim 1, wherein said isolated IKK.beta. comprises amino acid 36 to amino acid 300 of SEQ ID NO:15.

9. The isolated IKK.beta. of claim 1, wherein said isolated IKK.beta. comprises amino acid 603 to amino acid 642 of SEQ ID NO:15.

10. The isolated IKK.beta. of claim 1, wherein said isolated IKK.beta. comprises amino acid 458 to amino acid 486 of SEQ ID NO:15.

11. The isolated IKK.beta. of claim 1, wherein said isolated IKK.beta. comprises two or more sequences selected from the group consisting of amino acid 36 to amino acid 300 of SEQ ID NO:15, amino acid 603 to amino acid 642 of SEQ ID NO:15, and amino acid 458 to amino acid 486 of SEQ ID NO:15.

12. The isolated IKK.beta. of claim 1, wherein said isolated IKK.beta. comprises amino acid 36 to amino acid 300 of SEQ ID NO:15, amino acid 603 to amino acid 642 of SEQ ID NO:15, and amino acid 458 to amino acid 486 of SEQ ID NO:15.

13. A method of identifying an agent that modulates the specific association of an IKK.beta. and IKB protein, comprising the steps of: a) providing: the isolated IKK.beta. of claim 1; ii) I.kappa.B protein; and iii) said agent; b) contacting said isolated IKK.beta., said I.kappa.B protein, and said agent under conditions suitable for the specific association of said IKK.beta. and said I.kappa.B protein; and c) detecting an altered association of said IKK.beta. and said I.kappa.B protein in the presence of said agent, wherein said altered association identifies said agent as modulating the specific association of said IKK.beta. and said I.kappa.B protein.

14. The method of claim 13, wherein said I.kappa.B protein is chosen from one or more of I.kappa.B.beta. and I.kappa.B.beta..

15. A method of identifying an agent that modulates the specific association of an IKK.beta. and a protein chosen from one or more of IKB.beta. and IKB.beta., comprising the steps of: a) providing: i) the isolated IKK.beta. of claim 10; ii) said protein; and iii) said agent; b) contacting said isolated IKK.beta., said proteing, and said agent under conditions suitable for the specific association of said IKK.beta. and said protein; and c) detecting an altered association of said IKK.beta. and said protein in the presence of said agent, wherein said altered association identifies said agent as modulating the specific association of said IKK.beta. and said protein.

16. The method of claim 13, wherein said agent is a mutant I.kappa.B protein chosen from one or more of (1) mutant I.kappa.B.beta. containing amino acid substitutions for serine-32 and for serine-36, and (2) mutant I.kappa.B.beta. containing amino acid substitutions for serine-19 and for serine-23.

17. The method of claim 13, wherein said isolated IKK.beta. comprises SEQ ID NO:15.

18. A method for identifying an agent that alters IKK.beta. activity, comprising the steps of: a) providing: i) the isolated IKK.beta. of claim 1;

and ii) said agent; b) incubating said isolated IKK.beta. with said agent; and c) determining altered I.kappa.B kinase activity of said isolated IKK.beta. in the presence of said agent, wherein said altered I.kappa.B activity identifies said agent as altering IKK.beta. activity.

19. The method of claim 18, wherein said isolated IKK.beta. comprises a 300 kDa I.kappa.B kinase complex or a 900 kDa I.kappa.B kinase complex.

20. The method of claim 18, wherein said isolated IKK.beta. comprises SEQ ID NO:15.

Previous Doc Next Doc Go to Doc#

Hit List

Clear | Generate Collection | Print | Fwd Refs | Bkwd Refs | Generate OACS

Search Results - Record(s) 11 through 11 of 11 returned.

☐ 11. Document ID: US 5851812 A

L1: Entry 11 of 11 File: USPT Dec 22, 1998

US-PAT-NO: 5851812
DOCUMENT-IDENTIFIER: US 5851812 A

TITLE: IKK-.beta. proteins, nucleic acids and methods

DATE-ISSUED: December 22, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Goeddel; David V.	Hillsborough	CA		
Woronicz; John	South San Francisco	CA		

US-CL-CURRENT: 435/194; 435/252.3, 435/325, 536/23.2

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Da

Clear | Generate Collection | Print | Fwd Refs | Bkwd Refs | Generate OACS

Terms	Documents
5851812	11

Display Format: CIT Change Format

Previous Page Next Page Go to Doc#